
    
      PRIMARY OBJECTIVES:

      I. To assess whether 2 weeks of donor statin treatment reduces the risk of severe acute GVHD.

      SECONDARY OBJECTIVES:

      I. To assess whether 2 weeks of statin treatment of normal PBSC donors is feasible, tolerable
      and safe.

      OUTLINE:

      Donors receive atorvastatin orally (PO) beginning on day -14 and continuing until the last
      day of stem cell collection.
    
  